Overview
- The maker of da Vinci robots ended 2025 with 11,106 systems in use worldwide, up 12% year over year.
- Procedures performed on its systems grew about 18% in 2025, with management guiding for up to 15% growth in 2026.
- Roughly a quarter of revenue comes from robot sales, while instruments, accessories and services provide a larger recurring stream.
- Shares sit about 19% below their 2026 high and roughly 21% under the late‑2025 record, reflecting typical volatility with past 25%–30% drawdowns.
- The article contends that advances in AI and improving surgical outcomes support a durable growth outlook.